Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures

Background/Aim: Pancreatic adenocarcinoma is a highly malignant tumor. Synergistic combinations of anticancer agents for the effective treatment of pancreatic cancer patients are urgently needed. Here, we investigated the combined effect of celecoxib (CEL) and salirasib (SAL) on pancreatic cancer ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dongli, Ma, Yuran, Liu, Wenfeng, Ren, Xiang, Chen, Min, Xu, Xuetao, Sheng, Zhaojun, Zhang, Kun, Zhou, Renping, Goodin, Susan, Zheng, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378654/
https://www.ncbi.nlm.nih.gov/pubmed/32714082
http://dx.doi.org/10.7150/ijms.47546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378654/
https://www.ncbi.nlm.nih.gov/pubmed/32714082
http://dx.doi.org/10.7150/ijms.47546

Ejemplares similares